Navigating the labyrinth of healthcare technology pricing presents a formidable challenge for policymakers globally, as they attempt to strike a delicate balance between limited budgets and the imperative for innovation. This ongoing complexity is reflected in the diverse and intricate landscape of pricing policies for potentially innovative healthcare technologies (pIHTs) across Europe and other advanced economies. As each nation grapples with different approaches to managing affordability and access, the need for comprehensive data to align pricing strategies with health outcomes becomes increasingly apparent.
Identifying Price Determinants
The study reviewed literature from 2014 to 2023, scoping scientific articles and grey literature to uncover knowledgeable insights into price determinants informed by stakeholders. Two primary factors emerged as influential in the pricing of pIHTs: value-based determinants and the complex interplay of policies across European Economic Area (EEA) and Organisation for Economic Cooperation and Development (OECD) member states. These factors collectively shape the techniques policymakers employ to ensure affordability without stifling access.
Heterogeneity in Pricing Policies
A mosaic of policy interventions and implementation methods marks the landscape of pricing policies in EEA/OECD regions. Despite the common practice of external price referencing (EPR) aimed at short-term affordability, this strategy can exacerbate price disparities and impact patient access unfavorably. More integrated pricing models that account for the inherent value of pIHTs appear to foster better access outcomes, albeit often encountering hurdles in practicability and execution.
– Value-based pricing often links better to patient access but poses challenges in policy consistency.
– EPR may boost initial affordability but could lead to inequitable pricing across different markets.
– Heterogeneous policy interventions complicate the formulation of a cohesive pricing strategy.
– Limited focus observed on medical device pricing and lack of environmental considerations in existing policies.
While applying EPR remains prevalent across Europe, the preference for value-informed pricing tied with health technology assessment garners positive reactions concerning pIHT access within academic circles. Significant knowledge gaps persist, particularly regarding medical device pricing nuances and the scant integration of environmental considerations into pIHT pricing frameworks. To make informed decisions, it is crucial for stakeholders to work collaboratively, adopting broader considerations that encompass value implications and striving to integrate sustainable practices. This holistic approach could ensure not only equitable pricing but also encourage sustainable innovation in healthcare technology development. By addressing these gaps, we will better accommodate future challenges posed by rapid technological advancements in healthcare.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
